Invesco Mutual Fund launches Invesco India Pharma and Healthcare Fund
NFO period: 18th Aug - 01st Sep, 2026
Highlights of the NFO:
- Scheme type - An open ended equity scheme investing in Pharma, Healthcare and allied sectors
- Investment objective - To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
- Product suitability - This product is suitable for investors who are seeking to generate capital appreciation over long term. Investments predominantly in equity and equityrelated instruments of pharma, healthcare and allied companies.
- Minimum Application Amount - Rs. 1,000/- per application and in multiples of Re. 1/- thereafter
- Plan/ Options available - Regular plan & Direct plan having Growth Option and Income Distribution cum Capital Withdrawal (IDCW) Option (with Payout of Income Distribution cum capital withdrawal option and Reinvestment of Income Distribution cum capital withdrawal option).
- Fund Managers - Mr. Aditya Khemani
- Benchmark - BSE Healthcare TRI
(Mutual Fund investments are subject to market risks, read all scheme related documents carefully.)
This is a summary of a public announcement, shared for information. It is not a recommendation, and 2i WealthPlus Financial Services may not distribute every scheme mentioned. Disclaimer: Mutual Fund investments are subject to market risks, read all scheme related documents carefully. Past performance is not an indicator of future returns. 2i WealthPlus Financial Services acts solely as an AMFI-registered Mutual Fund Distributor (ARN: 266652) and earns trailing commissions paid by Asset Management Companies (AMCs) for mutual fund scheme distribution. In compliance with SEBI guidelines, we do not provide SEBI-registered investment advisory or portfolio management services.